

Weiwei Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6471095/publications.pdf>

Version: 2024-02-01

60
papers

2,879
citations

279701

23
h-index

197736

49
g-index

65
all docs

65
docs citations

65
times ranked

3030
citing authors

#	ARTICLE	IF	CITATIONS
1	The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 87.	7.1	433
2	An emerging function of circRNA-miRNAs-mRNA axis in human diseases. <i>Oncotarget</i> , 2017, 8, 73271-73281.	0.8	429
3	Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. <i>Molecular Cancer</i> , 2019, 18, 130.	7.9	261
4	CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. <i>Molecular Cancer</i> , 2018, 17, 137.	7.9	213
5	Hierarchical NiCo ₂ O ₄ nanosheets/nitrogen doped graphene/carbon nanotube film with ultrahigh capacitance and long cycle stability as a flexible binder-free electrode for supercapacitors. <i>Journal of Materials Chemistry A</i> , 2017, 5, 689-698.	5.2	131
6	Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. <i>Cancer Biomarkers</i> , 2018, 21, 299-306.	0.8	122
7	Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression. <i>Cancer Management and Research</i> , 2018, Volume 10, 5725-5734.	0.9	85
8	Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 775462.	1.8	59
9	Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. , 2022, 10, e004656.		59
10	Novel insights into circular RNAs in clinical application of carcinomas. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2183-2188.	1.0	57
11	m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 637-648.	2.3	53
12	Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 67-82.	2.3	52
13	Defective mitophagy in aged macrophages promotes mitochondrial DNA cytosolic leakage to activate STING signaling during liver sterile inflammation. <i>Aging Cell</i> , 2022, 21, .	3.0	45
14	Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 183-206.	2.0	44
15	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 694363.	1.8	42
16	Engineered exosomes for co-delivery of PGM5AS1 and oxaliplatin to reverse drug resistance in colon cancer. <i>Journal of Cellular Physiology</i> , 2022, 237, 911-933.	2.0	40
17	Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/nuclear factor- κ B (NF- κ B) pathway. <i>Bioengineered</i> , 2022, 13, 4786-4797.	1.4	39
18	The circ_0021977/miR-10b-5p/P21 and P53 regulatory axis suppresses proliferation, migration, and invasion in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 2273-2285.	2.0	38

#	ARTICLE	IF	CITATIONS
19	Single-cell RNA sequencing of immune cells in gastric cancer patients. <i>Aging</i> , 2020, 12, 2747-2763.	1.4	36
20	Clinical significance of CD8 ⁺ T cell immunoreceptor with Ig and ITIM domains in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. <i>Oncolmmunology</i> , 2019, 8, e1593807.	2.1	35
21	Circ-TTC17 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 751-758.	1.1	33
22	Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. <i>OncoTargets and Therapy</i> , 2016, 9, 455.	1.0	32
23	Upregulation of circ_0066444 promotes the proliferation, invasion, and migration of gastric cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2753-2761.	1.0	29
24	The emerging landscape of circular RNAs in immunity: breakthroughs and challenges. <i>Biomarker Research</i> , 2020, 8, 25.	2.8	24
25	Circ-ZDHHC5 Accelerates Esophageal Squamous Cell Carcinoma Progression in vitro via miR-217/ZEB1 Axis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 570305.	1.8	23
26	MGP promotes CD8 ⁺ T cell exhaustion by activating the NF- κ B pathway leading to liver metastasis of colorectal cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2345-2361.	2.6	22
27	ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4142-4153.	1.2	21
28	ROR2 knockdown suppresses breast cancer growth through PI3K/ATK signaling. <i>Aging</i> , 2020, 12, 13115-13127.	1.4	18
29	Health literacy and functional exercise adherence in postoperative breast cancer patients. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 781-786.	0.8	17
30	Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 647854.	1.3	17
31	CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 321.	2.0	17
32	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 771335.	1.3	15
33	circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD-L1 through NF- κ B pathway. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24003.	0.9	14
34	Circ-PTPDC1 promotes the Progression of Gastric Cancer through Sponging Mir-139-3p by Regulating ELK1 and Functions as a Prognostic Biomarker. <i>International Journal of Biological Sciences</i> , 2021, 17, 4285-4304.	2.6	13
35	HtrA serine proteases in cancers: A target of interest for cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111603.	2.5	12
36	Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24447.	0.9	12

#	ARTICLE	IF	CITATIONS
37	<p>Star Circular RNAs In Human Cancer: Progress And Perspectives</p>. OncoTargets and Therapy, 2019, Volume 12, 8249-8261.	1.0	11
38	Overexpression of lncRNA AFAP1’AS1 promotes cell proliferation and invasion in gastric cancer. Oncology Letters, 2019, 18, 3211-3217.	0.8	10
39	Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 3013-3036.	1.0	10
40	Treatment of patients with cancer using PD’1/PD’L1 antibodies: Adverse effects and management strategies (Review). International Journal of Oncology, 2022, 60, .	1.4	9
41	Circular RNAs as novel rising stars with huge potentials in development and disease. Cancer Biomarkers, 2018, 22, 597-610.	0.8	8
42	Emerging Landscapes of Tumor Immunity and Metabolism. Frontiers in Oncology, 2020, 10, 575037.	1.3	8
43	High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50’79’years in Southwest China. BMC Cardiovascular Disorders, 2022, 22, 2.	0.7	7
44	WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research, 2021, Volume 13, 2483-2498.	0.9	6
45	Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-16.	0.6	6
46	Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
47	Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target. Journal of Oncology, 2021, 2021, 1-18.	0.6	5
48	Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11. Bioengineered, 2021, 12, 11506-11519.	1.4	5
49	STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. IScience, 2021, 24, 103223.	1.9	4
50	Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016. PLoS ONE, 2020, 15, e0239674.	1.1	3
51	mRNA microarray profiling identifies a novel circulating HTRA2 for detection of gastric cancer. Journal of Clinical Laboratory Analysis, 2021, 35, e24054.	0.9	3
52	ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations. OncoTargets and Therapy, 2018, Volume 11, 1-8.	1.0	2
53	circPSMC3: ceRNA and tumor suppressor. Oncotarget, 2019, 10, 3433-3434.	0.8	2
54	Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of Oncology, 2022, 2022, 1-12.	0.6	2

#	ARTICLE	IF	CITATIONS
55	An isolated unusual digit metastasis from esophageal carcinoma: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2449-2452.	1.0	1
56	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
57	Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, e0239674.		0
58	Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, e0239674.		0
59	Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, e0239674.		0
60	Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, e0239674.		0